Last reviewed · How we verify
NCT03540472
Tacrolimus Treatment for Refractory PRCA
Phase 4 trial testing tacrolimus in Pure Red Cell Aplasia in 30 participants. Status unknown.
10 December 2018
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 10 June 2018 |
| Primary completion | 10 December 2018 |
| Estimated completion | 10 June 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- tacrolimus (TACROLIMUS) — full drug profile →
Conditions studied
- Pure Red Cell Aplasia — all drugs for Pure Red Cell Aplasia →
Sponsor
Peking Union Medical College Hospital
Who can join
Adults 18 to 80, any sex, with Pure Red Cell Aplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pure red cell aplasia (PRCA) is a kind of anemia characterized by severe reticulocytopenia and obvious bone marrow erythroblastic cells decreased. Cyclosporine and /or steroids are the first line therapy but some patients were refractory or intolerance to the treatment. The effects of the second line therapy are also not satisfactory and sometimes not available. The investigators aim to explore the efficacy and side-effect of tacrolimus for refractory PRCA.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03540472
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of tacrolimus
Trials testing the same drug.
- NCT05294666 — Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment · Phase 4 · completed
- NCT03737708 — A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA) · Phase 4 · completed
- NCT03178149 — A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due · Phase 1 · recruiting
- NCT03465969 — A Study to Compare the Finger Prick Whole Blood MITRA Assay Method With the Established Venepuncture Whole Blood Method · Phase 4 · completed
- NCT02466997 — Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITAC · Phase 3 · completed
Other recruiting trials for Pure Red Cell Aplasia
Currently open trials in the same condition.
- NCT06065852 — National Registry of Rare Kidney Diseases · recruiting
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03540472 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 30 May 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03540472.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing